Covid-19 vaccines: safety surveillance manual - Description and general safety considerations for implementation

Overview

With the early availability of the full sequence of the SARS-CoV-2 genome, developing a vaccine that could help countries to bring citizens’ lives back to normal is the highest priority for the global community. It is critical that vaccines are both effective and safe and can be manufactured in sufficient quantities to ensure that they are available globally. As of 12 November 2020, 258 candidate vaccines are in different stages of development: 205 in preclinical studies; 43 in phase I/II clinical studies; and 11 in phase III studies.